Medicare Part D operates as a hybrid program, leveraging both government subsidies and partnerships with private insurance companies to provide prescription drug coverage to Medicare beneficiaries. This collaboration aims to offer a diverse range of plan options while controlling costs through competition among insurers. However, despite its intentions, Part D frequently faces criticism due to the persistent issue of exorbitant medication costs for seniors in the United States. The reliance on private insurers, coupled with limited government negotiation power over drug prices, often results in inflated prescription costs and financial strain for beneficiaries. As a result, Medicare Part D is a focal point of scrutiny in discussions surrounding healthcare policy, with calls for reforms to address the affordability and accessibility challenges faced by seniors in need of vital medications.